Low weekly doses of doxorubicin and epidoxorubicin in second line chemotherapy of advanced breast cancer

B. Jereczek, J. Jassem, H. Karnicka-Mlodkowska, J. Tujakowski, J. Zaluski, K. Moszkowska-Kopij, I. Zander, E. Solska

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Study objectives were to assess the efficacy and tolerance of two anthracyclines: doxorubicin (DXR) and epidoxorubicin (EpiDX) given weekly at low doses in patients with advanced breast cancer not amenable to aggressive chemotherapy. One hundred and twenty two patients (age 32-82 years, median 56 years, median PS 2, range 0-4) were entered of whom 58 received DXR and EpiDX. The choice of one of the two anthracyclines used was left to the discretion of the treating physician. The two groups of patients were well balanced for age, previous therapy, PS and target lesions. Both anthracyclines were given i.v. weekly at a dose/course of 20 mg (DXR) and 30 mg (EpiDX). All patients were assessed for toxicity and 116 were assessed for response. An objective response (CR + PR) was seen in 24 of 58 DXR patients (41%) and in 26 of 64 those given EpiDX (41%). The median duration of response for both drugs was 6 and 5 months, respectively. Treatment was well tolerated. Alopecia, gastrointestinal, hematological and cardiac toxicities were mild and similar in patients given DXR and EpiDX. No toxicity was seen in about 40% of the patients. In conclusion, this study demonstrated usefulness and similar activity of low weekly doses of both anthracyclines. This approach seems to be a reasonable alternative to standard second line chemotherapy and is a treatment of choice in patients not amenable to more aggressive schedules.

Original languageEnglish
Pages (from-to)213-218
Number of pages6
JournalLibri Oncologici
Volume22
Issue number3
Publication statusPublished - 1993

Fingerprint

Doxorubicin
Breast Neoplasms
Drug Therapy
Anthracyclines
Alopecia
Appointments and Schedules
Therapeutics
Physicians
Pharmaceutical Preparations

Keywords

  • Advanced breast cancer
  • Anthracyclines
  • Epidoxorubicin
  • Weekly doxorubicin

ASJC Scopus subject areas

  • Oncology

Cite this

Jereczek, B., Jassem, J., Karnicka-Mlodkowska, H., Tujakowski, J., Zaluski, J., Moszkowska-Kopij, K., ... Solska, E. (1993). Low weekly doses of doxorubicin and epidoxorubicin in second line chemotherapy of advanced breast cancer. Libri Oncologici, 22(3), 213-218.

Low weekly doses of doxorubicin and epidoxorubicin in second line chemotherapy of advanced breast cancer. / Jereczek, B.; Jassem, J.; Karnicka-Mlodkowska, H.; Tujakowski, J.; Zaluski, J.; Moszkowska-Kopij, K.; Zander, I.; Solska, E.

In: Libri Oncologici, Vol. 22, No. 3, 1993, p. 213-218.

Research output: Contribution to journalArticle

Jereczek, B, Jassem, J, Karnicka-Mlodkowska, H, Tujakowski, J, Zaluski, J, Moszkowska-Kopij, K, Zander, I & Solska, E 1993, 'Low weekly doses of doxorubicin and epidoxorubicin in second line chemotherapy of advanced breast cancer', Libri Oncologici, vol. 22, no. 3, pp. 213-218.
Jereczek B, Jassem J, Karnicka-Mlodkowska H, Tujakowski J, Zaluski J, Moszkowska-Kopij K et al. Low weekly doses of doxorubicin and epidoxorubicin in second line chemotherapy of advanced breast cancer. Libri Oncologici. 1993;22(3):213-218.
Jereczek, B. ; Jassem, J. ; Karnicka-Mlodkowska, H. ; Tujakowski, J. ; Zaluski, J. ; Moszkowska-Kopij, K. ; Zander, I. ; Solska, E. / Low weekly doses of doxorubicin and epidoxorubicin in second line chemotherapy of advanced breast cancer. In: Libri Oncologici. 1993 ; Vol. 22, No. 3. pp. 213-218.
@article{4885ad40e766469ab4f2fe17180362cb,
title = "Low weekly doses of doxorubicin and epidoxorubicin in second line chemotherapy of advanced breast cancer",
abstract = "Study objectives were to assess the efficacy and tolerance of two anthracyclines: doxorubicin (DXR) and epidoxorubicin (EpiDX) given weekly at low doses in patients with advanced breast cancer not amenable to aggressive chemotherapy. One hundred and twenty two patients (age 32-82 years, median 56 years, median PS 2, range 0-4) were entered of whom 58 received DXR and EpiDX. The choice of one of the two anthracyclines used was left to the discretion of the treating physician. The two groups of patients were well balanced for age, previous therapy, PS and target lesions. Both anthracyclines were given i.v. weekly at a dose/course of 20 mg (DXR) and 30 mg (EpiDX). All patients were assessed for toxicity and 116 were assessed for response. An objective response (CR + PR) was seen in 24 of 58 DXR patients (41{\%}) and in 26 of 64 those given EpiDX (41{\%}). The median duration of response for both drugs was 6 and 5 months, respectively. Treatment was well tolerated. Alopecia, gastrointestinal, hematological and cardiac toxicities were mild and similar in patients given DXR and EpiDX. No toxicity was seen in about 40{\%} of the patients. In conclusion, this study demonstrated usefulness and similar activity of low weekly doses of both anthracyclines. This approach seems to be a reasonable alternative to standard second line chemotherapy and is a treatment of choice in patients not amenable to more aggressive schedules.",
keywords = "Advanced breast cancer, Anthracyclines, Epidoxorubicin, Weekly doxorubicin",
author = "B. Jereczek and J. Jassem and H. Karnicka-Mlodkowska and J. Tujakowski and J. Zaluski and K. Moszkowska-Kopij and I. Zander and E. Solska",
year = "1993",
language = "English",
volume = "22",
pages = "213--218",
journal = "Libri Oncologici",
issn = "0300-8142",
publisher = "University Hospital for Tumors",
number = "3",

}

TY - JOUR

T1 - Low weekly doses of doxorubicin and epidoxorubicin in second line chemotherapy of advanced breast cancer

AU - Jereczek, B.

AU - Jassem, J.

AU - Karnicka-Mlodkowska, H.

AU - Tujakowski, J.

AU - Zaluski, J.

AU - Moszkowska-Kopij, K.

AU - Zander, I.

AU - Solska, E.

PY - 1993

Y1 - 1993

N2 - Study objectives were to assess the efficacy and tolerance of two anthracyclines: doxorubicin (DXR) and epidoxorubicin (EpiDX) given weekly at low doses in patients with advanced breast cancer not amenable to aggressive chemotherapy. One hundred and twenty two patients (age 32-82 years, median 56 years, median PS 2, range 0-4) were entered of whom 58 received DXR and EpiDX. The choice of one of the two anthracyclines used was left to the discretion of the treating physician. The two groups of patients were well balanced for age, previous therapy, PS and target lesions. Both anthracyclines were given i.v. weekly at a dose/course of 20 mg (DXR) and 30 mg (EpiDX). All patients were assessed for toxicity and 116 were assessed for response. An objective response (CR + PR) was seen in 24 of 58 DXR patients (41%) and in 26 of 64 those given EpiDX (41%). The median duration of response for both drugs was 6 and 5 months, respectively. Treatment was well tolerated. Alopecia, gastrointestinal, hematological and cardiac toxicities were mild and similar in patients given DXR and EpiDX. No toxicity was seen in about 40% of the patients. In conclusion, this study demonstrated usefulness and similar activity of low weekly doses of both anthracyclines. This approach seems to be a reasonable alternative to standard second line chemotherapy and is a treatment of choice in patients not amenable to more aggressive schedules.

AB - Study objectives were to assess the efficacy and tolerance of two anthracyclines: doxorubicin (DXR) and epidoxorubicin (EpiDX) given weekly at low doses in patients with advanced breast cancer not amenable to aggressive chemotherapy. One hundred and twenty two patients (age 32-82 years, median 56 years, median PS 2, range 0-4) were entered of whom 58 received DXR and EpiDX. The choice of one of the two anthracyclines used was left to the discretion of the treating physician. The two groups of patients were well balanced for age, previous therapy, PS and target lesions. Both anthracyclines were given i.v. weekly at a dose/course of 20 mg (DXR) and 30 mg (EpiDX). All patients were assessed for toxicity and 116 were assessed for response. An objective response (CR + PR) was seen in 24 of 58 DXR patients (41%) and in 26 of 64 those given EpiDX (41%). The median duration of response for both drugs was 6 and 5 months, respectively. Treatment was well tolerated. Alopecia, gastrointestinal, hematological and cardiac toxicities were mild and similar in patients given DXR and EpiDX. No toxicity was seen in about 40% of the patients. In conclusion, this study demonstrated usefulness and similar activity of low weekly doses of both anthracyclines. This approach seems to be a reasonable alternative to standard second line chemotherapy and is a treatment of choice in patients not amenable to more aggressive schedules.

KW - Advanced breast cancer

KW - Anthracyclines

KW - Epidoxorubicin

KW - Weekly doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=0027731012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027731012&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027731012

VL - 22

SP - 213

EP - 218

JO - Libri Oncologici

JF - Libri Oncologici

SN - 0300-8142

IS - 3

ER -